

FREQUENTLY ASKED QUESTIONS

Q: Is it possible for a non-author to submit?

A: A non-author or third party may submit an abstract on behalf of the authors. The submitter does not need to be listed as an author on the abstract.

Q: Is there a limit to the number of abstracts an individual may co-author?

A: There is no limit to the number of abstracts an individual may co-author.

Q: Is there a limit to the number of authors per abstract?

A: There is no limit imposed by the Congress or the journal. However, where appropriate, authors may wish to submit on behalf of a study group to avoid an excessively long author byline.

Q: Do you accept encore abstracts? If so, what is your encore policy?

A: Encore abstracts will be considered but are unlikely to be accepted for oral presentation. If submitting an encore abstract, please tick the box in the submission system and provide details of the congress(es) at which the abstract was previously presented.

Q: Do you accept late breaker abstracts?

*A: Late breaker abstracts may be submitted. To be eligible to submit a late breaker abstract, a letter of intent must be submitted to the Congress Secretariat at hivglasgow@ashfieldmedcomms.com by the regular abstract submission deadline of **Friday 26 June 2026, 23:59 PDT**. The letter of intent should include the working title of the late breaker abstract, a short summary, and the reason for the late breaker request. Following acceptance of the late breaker request, you will receive a bespoke submission link. The late breaker submission deadline is **Friday 21 August 2026, 23:59 PDT**.*

Q: Do you accept industry-sponsored abstracts?

A: Industry-sponsored abstracts may be submitted. However, if your abstract is selected for oral presentation, and the Congress achieves EACCME accreditation, the oral presentation will need to be delivered by a non-industry presenter.

Q: What is your policy on the use of artificial intelligence (AI) in abstract and presentation development?

A: The use of AI to assist in refining language, improving grammar, and optimising structure is generally accepted, provided the core research and conclusions are verified by the human authors.

Q: When will abstract notifications be sent?

*A: Outcome notifications will be sent to the submitter by **Monday 14 September 2026**. If you have not received a notification email by this date, please contact the Congress Secretariat at hivglasgow@ashfieldmedcomms.com, quoting the reference number issued upon submission.*

Q: Is it possible for a non-author to present?

A: If an abstract is accepted, at least one named author must register for and attend the Congress to present the abstract in the assigned format (oral or poster). In exceptional circumstances, requests for a non-author presenter may be considered by the Congress on a case-by-case basis.

Q: Is there a limit to how many abstracts an author can present?

A: There is no formal limit to the number of abstracts an author can present. However, if an author group is offered more than one oral presentation, the Scientific Committee may ask that another co-author be nominated to present one of the abstracts.

Q: Do I need to register for the Congress and provide a printed poster for display at the meeting?

A: At least one author must register for the Congress and attend to present in-person. Poster presenters must install a printed poster on-site. ePoster stations will not be available at the Congress. Full details, including poster dimensions and installation instructions, will be provided upon notification of acceptance.

Q: Will the Congress offer a poster printing service?

A: A poster printing service is planned. Further details will be provided upon notification of acceptance.

Q: Will ePosters be required? If so, when is the submission deadline?

A: Submission of an ePoster is optional. As HIV Drug Therapy Glasgow 2026 is a hybrid meeting, if you do not submit an ePoster, online delegates will not be able to view your poster. The deadline for ePoster submission is expected to be 2–3 weeks prior to the meeting. ePosters may be accompanied by an audio file or MP4 video presentation. Full technical specifications and submission instructions will be provided upon notification of acceptance.

Q: Are QR codes allowed on posters? If so, will the Congress provide them?

A: QR codes may be included on posters and must be generated and managed by the authors/agencies developing the poster. QR codes must not link to commercial content.

Q: When will the abstract book be published?

*A: All accepted abstracts will be published in a supplement to the Journal of the International AIDS Society (JIAS). Abstracts will be published on **Saturday 7 November 2026**.*

Q: What is your embargo policy for abstracts, oral presentations, and posters?

*A: Titles of accepted abstracts will be released on the Congress website ~1–2 weeks prior to the meeting. Full abstracts will be published in a supplement to JIAS on **Saturday 7 November 2026**. The supplement will include late breakers and abstracts accepted for oral presentation unless release is deemed commercially sensitive and alternative arrangements have been agreed in advance with the Congress Secretariat. For abstracts accepted for oral presentation, whilst abstract text will be released on **Saturday 7 November 2026**, additional data contained within the presentation must not be publicly disclosed before the start of the Congress session in which the oral presentation is being delivered. Some oral presenters may also display their findings as a poster, which will be on display from **Sunday 8 November 2026**. In line with the above oral presentation policy, data contained within the associated poster must not be publicly disclosed before the start of the Congress session in which the oral presentation is being delivered. For abstracts accepted for poster presentation, data contained within the poster should not be publicly disclosed until posters are displayed on **Sunday 8 November 2026**.*

Q: Who owns the copyright of abstracts and what type of license are they published under? Who owns the copyright of presentations?

A: Authors retain copyright of their abstracts, with first publication rights granted to JIAS. Abstracts will be published under the [Creative Commons Attribution \(CC BY\) license](#). The license allows third parties to share the published work (copy, distribute, transmit) and to adapt it under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear. Authors retain copyright of their presentations; anyone wishing to reuse presentation content should reach out to a member of the author group for permission.